Cargando…
β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now?
β-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for β(1) vs β(2) receptors, intrinsic sympathomimetic activity (ISA), and vasodilatory properties (through β(2) stimulation, α receptor blockade or nitric oxide release). These drugs are indicated for the management...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197620/ https://www.ncbi.nlm.nih.gov/pubmed/34135591 http://dx.doi.org/10.2147/VHRM.S285907 |
_version_ | 1783706959994683392 |
---|---|
author | Pathak, Atul Mrabeti, Sanaa |
author_facet | Pathak, Atul Mrabeti, Sanaa |
author_sort | Pathak, Atul |
collection | PubMed |
description | β-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for β(1) vs β(2) receptors, intrinsic sympathomimetic activity (ISA), and vasodilatory properties (through β(2) stimulation, α receptor blockade or nitric oxide release). These drugs are indicated for the management of arterial hypertension, heart failure or ischemic heart disease (IHD; eg angina pectoris or prior myocardial infarction). Most of the benefit of β-blockade in these conditions arises from blockade of the β(1) receptor, and, in practice, the addition of ISA appears to reduce the potential for improved clinical outcomes in people with heart failure or IHD. Aspects of the benefit/risk balance of β-blockers remain controversial, and recent meta-analyses have shed new light on this issue. We have reviewed the current place of cardioselective β-blockade in hypertension, IHD and heart failure, with special reference to the therapeutic profile of a highly selective β(1)-adrenoceptor blocker, bisoprolol. |
format | Online Article Text |
id | pubmed-8197620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-81976202021-06-15 β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? Pathak, Atul Mrabeti, Sanaa Vasc Health Risk Manag Review β-blockers are a heterogeneous class of drugs, with varying selectivity/specificity for β(1) vs β(2) receptors, intrinsic sympathomimetic activity (ISA), and vasodilatory properties (through β(2) stimulation, α receptor blockade or nitric oxide release). These drugs are indicated for the management of arterial hypertension, heart failure or ischemic heart disease (IHD; eg angina pectoris or prior myocardial infarction). Most of the benefit of β-blockade in these conditions arises from blockade of the β(1) receptor, and, in practice, the addition of ISA appears to reduce the potential for improved clinical outcomes in people with heart failure or IHD. Aspects of the benefit/risk balance of β-blockers remain controversial, and recent meta-analyses have shed new light on this issue. We have reviewed the current place of cardioselective β-blockade in hypertension, IHD and heart failure, with special reference to the therapeutic profile of a highly selective β(1)-adrenoceptor blocker, bisoprolol. Dove 2021-06-08 /pmc/articles/PMC8197620/ /pubmed/34135591 http://dx.doi.org/10.2147/VHRM.S285907 Text en © 2021 Pathak and Mrabeti. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Pathak, Atul Mrabeti, Sanaa β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? |
title | β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? |
title_full | β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? |
title_fullStr | β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? |
title_full_unstemmed | β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? |
title_short | β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? |
title_sort | β-blockade for patients with hypertension, ischemic heart disease or heart failure: where are we now? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197620/ https://www.ncbi.nlm.nih.gov/pubmed/34135591 http://dx.doi.org/10.2147/VHRM.S285907 |
work_keys_str_mv | AT pathakatul bblockadeforpatientswithhypertensionischemicheartdiseaseorheartfailurewherearewenow AT mrabetisanaa bblockadeforpatientswithhypertensionischemicheartdiseaseorheartfailurewherearewenow |